Shanghai, China

Chong Ding

USPTO Granted Patents = 2 

Average Co-Inventor Count = 12.0

ph-index = 1

Forward Citations = 7(Granted Patents)


Company Filing History:


Years Active: 2018-2021

Loading Chart...
2 patents (USPTO):

Title: Innovations by Chong Ding in Neurological Treatments

Introduction

Chong Ding is an accomplished inventor based in Shanghai, China. He has made significant contributions to the field of neurological treatments through his innovative research and development. With a total of 2 patents, Ding's work focuses on the use of TrkB binding agonists for treating various neurological disorders.

Latest Patents

Chong Ding's latest patents include a groundbreaking invention related to TrkB binding agonists. This invention pertains to the use of these agonists in the treatment of neurological disorders and other related conditions. The patent details specific TrkB binding agonists that comprise CDRs, variable regions, heavy and light chains, along with variant sequences thereof. This innovative approach aims to provide new therapeutic options for patients suffering from neurological issues.

Career Highlights

Chong Ding is currently associated with GlaxoSmithKline Intellectual Property Development Limited, where he continues to advance his research in the field of neurological treatments. His work has garnered attention for its potential impact on improving patient outcomes in various neurological disorders.

Collaborations

Chong Ding collaborates with notable professionals in his field, including Tejinder Kaur Bhinder and Xu Feng. These collaborations enhance the research and development process, leading to more effective solutions for neurological challenges.

Conclusion

Chong Ding's innovative contributions to the field of neurological treatments through his patents highlight his dedication to improving healthcare. His work with TrkB binding agonists represents a significant advancement in the treatment of neurological disorders.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…